Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bought this cos of its growing healthcare business making medical dressings etc. Convatec obviously felt threatened enough by it to renege on a big contract. Market is valuing it as a cyclical industrial rather than as a healthcare company. CEO hasn’t bought any shares at market price for several years until the recent placing at 105p so is a vote of confidence. Onshoring of supply chains particularly in healthcare should help.
Bought some today market are recovering this should start moving
I have bought a few of these. They have taken a bit of a clogging recently but hopefully now getting it together..
SCPA..............looks solid.
May 14 (Reuters) – Scapa Group PLC :
Scapa Group Plc - Received Credit Committee Approval From Its Lending Banks For A New £15 Million Short-term Facility,/b>
Scapa Group Plc - Announces Its Intention To Carry Out A Placing Of New Ordinary Shares Of 5 Pence Each
Scapa Group Plc - Group Is Expected To Deliver Record Revenues For Year Ended 31 March 2020, Despite Loss Of Convatec Contract
Scapa Group Plc - Currently Executing A Well-developed Covid-19 Action Plan Focused On Cash Management And Actions Taken To Preserve Liquidity
Scapa Group Plc - Expecting A Period Where Revenues Will Be Substantially Impacted, Particularly In Q1 Fy 2021 And In Early Q2 Fy 2021
Scapa Group Plc - Expecting Returning To More Normal Levels, And In-line With Management's Pre-covid-19 Budget, From Q3 Fy 2021 Onwards
Scapa Group Plc - Trading Profit For Fy 2020 Is Expected To Be Approximately £28 Million
Scapa Group Plc - Under Covid-19 Scenario, Group Is Expecting To Generate Fy
2021 Revenue Of Around £272 Million
Scapa Group Plc - Believe That Revenue And Profits Will Recover In Fy 2022
Scapa Group Plc - Expected That Group Revenue Will Grow By Between 5 And
10 Per Cent. From Fy 2021 Level In Fy 2022
Source text for Eikon: ... Further company coverage: SCPA.L
SCPA Scarpa.................looks like good solid business here.
https://www.investegate.co.uk/scapa-group-plc--scpa-/rns/trading-update--financing-and-proposed-placing/202005140700098407M/
From what i hear going into making masks at a reasonable and profitable rate/sp.
https://uk.advfn.com/p.php?pid=legacydaily&epic=L^SCPA&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=200&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES
Just had a punt on SCPA Scarpa....a working buy trade.
Sold it yesterday for a nice profit...............now down 5.23%
Silly really silly.
Any time now about to present there face medical MASKS for the public.
Scarpa SCPA........breaking away from that bottom foundation on the chart, up over 8%
https://uk.advfn.com/p.php?pid=legacydaily&epic=L^SCPA&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=200&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES
Bought some today
SCPA SCAPA Group.........trying to breakaway from the base, currently up over 4% with a big seller which as held it back. Hoping seller as finished.
https://uk.advfn.com/p.php?pid=legacydaily&epic=L^SCPA&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=200&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES
masks not related to covid I think.
Lifted from advfn.....
Scapa - Factories “essential business” status
108p Epic code: SCPA
(Sharewatch) • I have been watching Scapa (SCPA; 108p) for a re-entry point for some time. First time round on SCSW we did very well, tipping the shares in Nov‘11 at 47p and selling at 355p in Dec.’18.
Back in 2011, Scapa’s mainstay was industrial tape. These are tapes based on silicon, acrylic or other materials and fall into a range of applications where there is a need to attach, identify or protect something. Scapa’s portfolio ranges from masking tape, tape for identification of electrical wiring right through to tape for sticking a Peugeot badge on the grill of a car; tapes are usually sold under the brand of its OEM.
In 2008 the business came unstuck in the credit crunch nastiness. Almost overnight, when houses stopped being built and cars stopped selling, Scapa's distributors began to destock and against the background of a bloated cost base, debts ballooning and a large pension deficit, Scapa could easily have disappeared into the mists of time.
But it survived and under chief executive Heejae Chae, an old Volex-hand, Scapa was radically reshaped. Costs were cut and disposals of non-core parts made and Chae’s cool head approach was to transition the business into the higher margin and higher growth medical sector. The products that Scapa targeted were based on silicon gel eg. disposable adhesive pads for medical devices such as heart monitors that are attached to patients; transdermal patches, which slowly release drugs through the skin; and also advanced woundcare, making sheeting for plasters. Chae’s insight was to target turnkey or one-stop-shop packaged contracts, which landed big multi-year parcels of work. This culminated in three technology transfers of manufacturing assets. The biggest was Systagenix’s site in Yorkshire for £31.4m in 2018. It brought in a team of R&D scientists, a new microbiology lab and a dedicated gamma sterilisation facility.
But the deal pushed a rival’s nose out of joint (ConvaTec) causing it to abandon its own US$30m contract with Scapa. Scapa reacted by cutting its labour outgoings in a bid to mitigate the fallout and Chae reversed his earlier decision to retire in order to put out the fire. Scapa says it did no wrong and has filed for damages of US$83.8m.
On Numis’ forecast eps of 13.2p for the year just ended (Scapa says it has met forecasts) and 15.1p for the year started 1 April, the PE falls to 7.2, which is not demanding for a medtech outsourcer. All Scapa’s sites have been assigned “essential business” status, which means they are up and running. Maybe some sites could be repurposed to make masks. I don’t know when but somewhere up ahead there will be a big buy opportunity.
Volume gradually picking up.
Tipped in this weekends SCSW tip sheet. Ready for making masks ?.
SCPA starting to move up now.
https://uk.advfn.com/p.php?pid=legacyintra&epic=L^SCPA&type=1&size=3&period=a&freq=1&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES
I think you're right. Small retail purchases seem to drive significant price changes in this company.
However I'm holding rather than topping up. Scapa have now had three negative news items in the last few months and still have a high PE of 36. The next announcement had better be positive.
Talk about oversold and undervalued. An appropriate SP for this to have settled to would have been 230-240. As we see time and time again in this scenario this will drift back upwards over the next 24-48 hours
I now notice that short positions increased
In January. So someone knew somefink .
196.45 - 197.42
good recovery potential
Alliance News) - Adhesive products manufacturer Scapa Group PLC on Wednesday warned its annual trading profit will be below market expectations, tumbling more than 20% from the prior year's levels.
Shares in the company slid 34% to 180.00 pence each in early trade on Wednesday morning.
Revenue for the year ending March 31 is expected to be broadly in line with market expectations at GBP306 million, though this would represent a 1.9% decline from GBP311.8 million.
Trading profit will come in at GBP28 million, "significantly below consensus", Scapa cautioned, and 27% lower than the GBP38.2 million from the year prior.
Promisingly for Scapa however, Healthcare unit revenue will be "slightly ahead of market expectations", at GBP139 million, and will grow year-on-year despite the loss of a contract with medical devices maker ConvaTec Group PLC.
In its interim report, Scapa said it parted with GBP9.2 million in legal costs, severance fees, inventory write-offs and asset impairments, related to the loss of the ConvaTec deal.
In June, Scapa said it was seeking legal counsel after receiving notice from a ConvaTec unit, of the early termination of a supply agreement between the companies. Scapa in July added that it was eyeing USD83.8 million in damages.
Industrial revenue meanwhile will come in an at GBP168 million, edging below market forecasts, Scapa warned.
"This is primarily the result of adverse macroeconomic conditions, particularly in the automotive and specialty products markets," the company explained.
Scapa expects to report its full-year results on May 19.
Scapa added: "We believe that we have the right vision and strategy to capitalize on the outlook and opportunities for Healthcare and Industrial. Our Healthcare franchise is well positioned to benefit from the changes in the medical device market and whilst we expect the macro-environment to remain challenging, we will focus on cost reductions to drive the margin in Industrial to historical levels."
By Eric Cunha; ericcunha@alliancenews.com
Huge over-reaction to profit warning
Am in for a recovery
Anyone any ideas what is driving the recent steady increase in the share price?
Moving Average now says Strong Buy
so maybe now we shall see the 320p target I forecast back in August
https://www.britishbulls.com/m/SignalPage.aspx?lang=en&Ticker=SCPA.L
Signal Update
Our system’s recommendation today is to BUY. The pattern finally received a confirmation because the prices crossed above the Stop Loss level which was at 243.00, and our valid average buying price stands now at 244.26. The previous SELL signal was issued on 25/11/2019, 4 days ago, when the stock price was 238.00. Since then SCPA.L has risen by +2.63%.
Market Outlook
A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed and a BUY signal is generated. Market wants to reward the bulls. It may be now the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd.
Walking back down to 200p? Buying opportunity I would have thought.
Perfect storm brewing. Best sitting on cash for the time being imho.